Last reviewed · How we verify

NCT06181201: Neo-Flo-Rect

Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer

Terminated Last updated 18 March 2026
What this trial tests

trial testing Stool collection in Cancer of Rectum in 2 participants. Terminated before completion.

Timeline
19 February 2024
Primary endpoint
8 October 2024
8 October 2024

Quick facts

Lead sponsorCentre Oscar Lambret
StatusTerminated
Study typeOBSERVATIONAL
Enrollment2
Start date19 February 2024
Primary completion8 October 2024
Estimated completion8 October 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Oscar Lambret — full company profile →

Who can join

18 and older, any sex, with Cancer of Rectum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, single-centre study (RIPH3) for patients with rectal cancer soon to be treated with chemotherapy (+/- neo-adjuvant radio-chemotherapy) looking at the relationship between the composition of the gut microbiota before treatment and the tumour response after chemotherapy +/- radio-chemotherapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Stool collection

Trials testing the same drug.

Other recruiting trials for Cancer of Rectum

Currently open trials in the same condition.

Other Centre Oscar Lambret trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06181201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing